Portal Instruments

What Portal Instruments does

Portal Instruments is an MIT spinout founded in 2014 and headquartered in Cambridge, Massachusetts, that develops needle-free and needle-assisted drug delivery platforms for subcutaneous injection of high-viscosity biologics. Its core technology is a MIT-licensed linear Lorentz-force actuator that drives a computer-controlled high-pressure jet stream through a disposable cartridge made of cyclic olefin polymer, delivering formulations above 50 cP viscosity and up to 2 mL in volume in under 0.5 seconds. The product portfolio consists of two platforms: PRIME, a needle-free jet injector, and PRIME NEXUS, a reusable electromechanical autoinjector compatible with standard 1mL, 2.25mL, and 5mL pre-filled syringe containers. The company has accumulated at least 12 granted US patents and operates an ISO 13485:2016-certified quality system.

Portal Instruments operates a pure B2B platform-licensing model and does not sell products directly to consumers or healthcare providers. Revenue is generated through feasibility study fees, milestone-based co-development agreements with pharmaceutical partners, and future per-unit royalties on commercialized drug/device combination products. Its customer base consists of pharmaceutical and biotechnology companies developing injectable biologics for chronic conditions, with publicly visible engagements including a co-published validation study with Regeneron and a multi-million-dollar development agreement signed in March 2026 with an undisclosed biotech to advance PRIME NEXUS toward clinical readiness by Q1 2027. The company is backed by strategic investor Gerresheimer AG, which provides manufacturing and industrialization support, alongside earlier venture investors including 5AM Ventures, Sanofi, Takeda Ventures, and PBJ Capital.

Name

Portal Instruments

Legal name

Portal Instruments, Inc.

Website

https://portalinstruments.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Portal Instruments is an MIT spinout that develops needle-free and needle-assisted drug delivery platforms for subcutaneous injection of high-viscosity biologics, licensing its technology to pharmaceutical and biotech partners through co-development agreements.

Ownership category

akta.pro rank

Product category

Drug Delivery Devices

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps) (HLAHAIAM)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Needle-free injection
• Drug delivery devices
• Autoinjector technology
• Biologic drug delivery
• Subcutaneous injection

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Platform Licensing to Pharmaceutical Partners: Portal licenses its drug delivery technology platform to pharmaceutical and biotech companies. The platform consists of the reusable injector device and disposable drug cartridge, which are completed and commercialized through biopharma partners. Revenue is generated through licensing fees, development payments, and per-unit royalties on commercialized combination products.
2. Co-Development Agreements: Portal enters into multi-million-dollar development agreements with pharma partners to advance its devices toward clinical readiness for specific drug formulations. These agreements provide upfront and milestone-based development funding.
3. Feasibility Study Services: Portal offers feasibility studies to pharmaceutical companies to evaluate compatibility of their drug formulations with Portal's delivery platform, generating study fees and establishing commercial relationships.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Portal Instruments develops and licenses a proprietary drug delivery platform consisting of two product lines: the PRIME needle-free jet injection system and the PRIME NEXUS reusable needle-assisted electromechanical autoinjector. The platform uses an MIT-licensed linear Lorentz-force actuator to deliver high-viscosity biologics subcutaneously in less than half a second, and is commercialized through co-development and licensing agreements with pharmaceutical and biotechnology partners.

Product overview

Portal Instruments offers a drug delivery platform consisting of two integrated products: PRIME (needle-free jet injection platform) and PRIME Nexus (needle-assisted reusable autoinjector). Both products share core technology including a linear actuator platform and fluid dynamics expertise. PRIME uses high-pressure jet injection to deliver medications through the skin without a needle, while PRIME Nexus applies similar engineering principles in a needle-assisted format. The platform includes disposable components (cartridges and cassettes) designed for use with pharmaceutical partners' drug formulations.

Differentiator

Problem solved

Functional benefit

Brands

• PRIME: Portal's needle-free injection platform technology that delivers high-viscosity biologics through a narrow, hair-thin stream in less than a second.
• PRIME NEXUS

Products and services

• PRIME Needle-free injection platform that delivers high-viscosity biologics through a narrow, hair-thin stream in less than a second using computer-controlled high-pressure jet injection. Consists of a reusable injector and disposable drug cartridge, licensed to pharmaceutical and biotech partners for self-administration of injectable therapies at home.
• PRIME NEXUS A reusable, needle-assisted electromechanical autoinjector platform that delivers high-viscosity biologics with tailored injection depth, volume flexibility, and controlled injection times. Compatible with 1mL, 2.25mL, and 5mL pre-filled syringe (PFS) container formats. Targeted at pharmaceutical partners developing combination products for chronic disease self-administration.
• Portal Cartridge Disposable primary drug container made of cyclic olefin polymer (COP) used in Portal's needle-free drug delivery platform. Equipped with a precision nozzle that generates the hair-thin jet of medication, designed to fit standard fill-finish lines and hold drugs for long periods.

Quantifiable outcome

• 76% of patients preferred PRIME needle-free injection over prefilled syringe; 76% reported higher likelihood of medication adherence with PRIME
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Undisclosed Biotech CompanycoreStrategic or Co-development Partner · 17 March 2026Portal Instruments signed a multi-million-dollar development agreement with a leading biotech company in March 2026 to advance PRIME NEXUS toward clinical readiness by Q1 2027. The program focuses on delivering a high-volume, high-viscosity formulation with improved injection times. Portal will finalize device industrialization, complete verification and validation testing, and establish manufacturing readiness by end of 2026 for clinical submission.
• Regeneron PharmaceuticalscoreStrategic or Co-development Partner · 16 October 2025Portal Instruments and Regeneron co-published a study in Bioengineering & Translational Medicine demonstrating Portal's PRIME needle-free injection technology's ability to deliver high-viscosity monoclonal antibody formulations effectively. The study provided crucial data on volume flexibility and tailored injection depths, directly informing the development of the PRIME NEXUS platform. Regeneron's expertise in developing high-concentration monoclonal antibodies made them an ideal partner to rigorously challenge Portal's needle-free platform.
• Gerresheimer AGcoreStrategic or Co-development Partner · 9 May 2022Gerresheimer AG, a leading provider of drug delivery systems for pharma, biotech and cosmetics, made a strategic investment in Portal Instruments in May 2022. The partnership aims to transform the administration of injectable medicines and improve the patient experience for chronic diseases. Gerresheimer contributes manufacturing expertise, primary container capabilities, and industrialization support, while Portal contributes its innovative needle-free jet injection technology. Gerresheimer CEO Dietmar Siemssen called it a milestone in their strategy to offer unique and innovative solutions to clients.
• The Sumaira Foundation (TSF)minorOthers · 23 March 2021Portal Instruments partnered with The Sumaira Foundation for NMOSD (Neuromyelitis Optica Spectrum Disorder), a 501(c)(3) patient advocacy organization founded by an NMO patient. Both organizations share a vision of creating a better experience and improved treatment options for NMO patients. TSF Founder Sumaira Ahmed expressed enthusiasm about introducing Portal's needle-free device to the NMO patient community as an alternative to frequent infusion treatments.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• PharmaJet: PharmaJet develops needle-free jet injection technology for vaccine and drug delivery, the most direct competitor to Portal's PRIME needle-free platform with a comparable mechanism (high-pressure liquid jet) and overlapping pharma/biotech customer base.
• Crossject: Crossject develops needle-free, pre-filled, single-use injection systems for emergency and chronic therapeutics using proprietary jet-injection technology — directly comparable mechanism and use cases to Portal's PRIME needle-free platform.

Broad incumbents

• SHL Medical: SHL Medical is one of the largest developers of advanced autoinjectors and pen injectors for pharma combination products, competing with Portal for the same biologics-delivery partnership dollars with a much broader installed commercial base.
• West Pharmaceutical Services: West Pharmaceutical Services is a leading provider of drug delivery components (including elastomeric closures, pre-filled syringe systems, and autoinjector platforms) serving nearly every major pharma — a primary incumbent Portal must displace for partnership share.
• Ypsomed: Ypsomed manufactures a wide range of self-injection devices including autoinjectors and pen systems for pharma and biotech, and is a frequent partner for high-viscosity biologics — a direct competitor in the PFS-based autoinjector space where PRIME NEXUS plays.
• Stevanato Group: Stevanato Group is a global provider of drug containment, drug delivery, and diagnostic solutions including the Aidaptus autoinjector platform. It competes with Portal's PRIME NEXUS for pharma combination-product partnerships in injectable biologics.
• Gerresheimer AG: Gerresheimer is both a strategic investor/partner in Portal and a broad provider of syringes, cartridges, and drug-delivery systems to global pharma — making it simultaneously a partner and an incumbent competing for the same pharma combination-product programs.
• Becton Dickinson (BD): BD is one of the largest medical device companies globally with a major Pharmaceutical Systems segment supplying prefilled syringes, autoinjectors, and wearable injectors — a broad incumbent competing across the drug-delivery device landscape Portal addresses.
• Bespak (Recipharm): Bespak (now part of Recipharm) develops drug delivery devices including inhalers and autoinjectors for pharma partners, and is a relevant comparable for PRIME NEXUS given overlapping customer base and device platform positioning.

Emerging players

• Halozyme Therapeutics (Antares Pharma): Halozyme acquired Antares Pharma in 2022 to access its auto-injector and specialty injectable delivery platform for high-viscosity biologics — a comparable technology platform targeting the same pharma combination-product opportunity Portal addresses with PRIME NEXUS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/portaltx
• LinkedInlinkedin.com/company/portal-instruments

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Portal Instruments